Podcasts about zepbound

In this Trending Health series, Vynamic team members will highlight how different sectors of the health industry are evolving to meet the demands of today's ever-changing healthcare landscape through value creation and strategic transformations.In this episode, Mindy McGrath, Saurabh Raman, and Ryan Hummel dive into how payers are shifting from short-term cost cutting to long-term strategic transformation as a result of rising costs, policy upheaval, and evolving consumer demands.To learn more about how we can help your team navigate these strategic decisions, reach out to Saurabh.Raman@vynamic.com and Ryan.Hummel@vynamic.com. Podcast Tags: healthcare, health plan, healthcare strategy, health innovation, strategic transformation Source Links:Medical cost trend: Behind the numbers 2025 UnitedHealth reports highest medical costs since COVID-19 pandemic's start New Evernorth program to cap out-of-pocket costs for Wegovy, Zepbound at $200 Spending growth on GLP-1s outpaces specialty drugs: Evernorth study Elevance Health Reports First Quarter 2024 Results Panel – Mindy McGrath, Saurabh Raman, Ryan Hummel Research & Production – Julia Morrison, Saurabh Raman, Ryan Hummel, Everly PetruzzelliRecording & Editing – Mike Liberto, Rachel SkoneckiFor additional discussion, please contact us at TrendingHealth.com. 

Americans are unusually overweight and chronically ill compared to similarly rich countries. This episode presents a grand, unified theory for why that's the case. Our food environment has become significantly more calorie-rich and industrialized in the past few decades, sending our obesity rates soaring, our visceral fat levels rising, and our chronic inflammation surging. The result is an astonishing rise in chronic illness in America. That's the bad news. The good news is that GLP-1 drugs, like Ozempic and Zepbound, seem to be astonishingly successful at reversing many of these trends. This episode blends two interviews with Dr. David Kessler and Dr. Eric Topol. Kessler was the commissioner of the Food and Drug Administration under the Bush and Clinton administrations, from 1990 to 1997. He helped lead Operation Warp Speed in its final months. He is the author of the book 'Diet, Drugs, and Dopamine.' Topol is a cardiologist and the founder and director of the Scripps Research Translational Institute. He is the author of the book 'Super Agers.' If you have questions, observations, or ideas for future episodes, email us at PlainEnglish@Spotify.com. Host: Derek Thompson Guests: Dr. David Kessler and Dr. Eric Topol Producer: Devon Baroldi Learn more about your ad choices. Visit podcastchoices.com/adchoices

It's only June. That means you still have six full months to change your life. Seriously. Who do you want to be when the ball drops on December 31st?Are you going to be crying in the bathroom again because nothing fits? Googling “how to lose weight fast” for the hundredth time? Or are you going to feel proud as hell that you didn't give up on yourself this time?In this episode, I'm talking about what's actually possible in six months and how showing up with consistency (not perfection!) can transform how you feel, how you live, and how you see yourself.If you're tired of starting over every Monday, hating your life, emotionally eating your days away, and waiting for “the right time,” this is your wake-up call.Let's talk about who you could be by the end of the year and how to start becoming her now.

SUPPORT OUR WORK AND GET MORE NEWS! https://linktr.ee/manonthemounjaro

 We know GLP-1 meds are still a hot topic, so wanted to share our journey with you all. We both came to the decision to start taking Zepbound after coming off Mounjaro in 2023. Tune in and listen to why we chose to start Zepbound, what method we are using and what we hope to achieve. In this episode, we also discuss what we learned from Mounjaro just a few years ago to help us prepare for part 2 of this journey. We both spoke to our doctors and explained what we were hoping to achieve and they were both on board. We are THRILLED that medical professionals are willing to help fight this disease of obesity, no matter what it takes! And we are both fortunate enough to have those caring and invested doctors to aid us in this journey. Both doctors covered with us how to properly pull the injection and how to administer it. Explained possible side effects, talked about diet and exercise in a caring and helpful manner. All the things that we deserve as humans in this battle for health! Our advice? If your doctor isn't willing to walk the path with you... FIND A NEW DOCTOR! Like now! The only missing puzzle piece here is to get the insurance companies up to speed. Neither of our insurance companies will cover the drug. So, we had to seek alternate routes to make it affordable. Tune in if you're curious to hear more about that, as we explain it in detail in this episode. We are excited to kick off this new journey and we're looking forward to taking you along for the ride! Follow Justy & Steph on Instagram, where they share their weight loss journey and road to living a happy & healthy lifestyle.@we.are.losing.it If you prefer video to see us talk through our topics, you can watch us on YouTube. https://youtube.com/@wearelosingitShow your support by hitting download, like & subscribe! We truly appreciate each and every one of you!!

Je leest het goed. De rijkste man van de wereld heeft miljarden nodig. Geld dat 'ie gebruikt om zijn AI-imperium uit te bouwen. Het moet dé concurrent worden van OpenAI. Een bedrijf dat dan weer écht in oorlog ligt met Microsoft.We hebben het er deze aflevering over. Dan hebben we het ook over die echte oorlog. Die tussen Israël en Iran. In Iran smeken ze president Trump om een wapenstilstand in te lassen, maar daar heeft hij geen trek in. Waardoor de onzekerheid op de beurs (voor jou) nog langer aanhoudt.We ontdekten trouwens dat het ondanks die oorlog prima beleggen is in Tel Aviv. Nou ja prima. Fantastisch. Waarom dat is, je raadt het al: daarvoor moet je toch echt luisteren.Hoor je ook meer over een miljardenovername van Eli Lilly en de handelsdeal die Trump heeft gesloten met de EU. Of was het nu met het Verenigd Koninkrijk? See omnystudio.com/listener for privacy information.

Ian Bremmer, president of the Eurasia Group, joins "CBS Mornings" to break down a weekend of deep division in the U.S., as millions protested President Trump and his military parade, and deadly new strikes between Iran and Israel raised fears of a wider regional war in the Middle East. The jury in Karen Read's retrial began deliberations Friday afternoon and will continue Monday. Read is facing three charges in the 2022 death of her police officer boyfriend, John O'Keefe, including second-degree murder. Her first trial ended with a hung jury. Pharmaceutical giant Eli Lilly announced a price cut for its drug, Zepbound, for people who aren't using insurance. CBS News' Nancy Chen reports on the qualifications for the discount and what the cost reduction will be. Artificial intelligence is being used to create realistic video and audio to impersonate people, in some cases looking for love or deceiving companies looking to hire. In a 2024 study, half of the businesses surveyed said they'd experienced AI deepfake fraud. CBS News MoneyWatch correspondent Kelly O'Grady reports. In this week's "Beg-Knows America," CBS News contributor David Begnaud revisits the life-changing world of high school speech and debate, an activity that shaped his own path. He meets the inspiring young voices featured in the new documentary "SPEAK," tackling grief, identity, and advocacy with extraordinary courage. Consumer Reports' deputy editor Brian Vines joins "CBS Mornings" to share the latest sunscreen testing results, including top-rated picks and expert tips to keep you and your family safe in the sun this summer. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Welcome to the first episode of Diamond Paint and Podcast — a cozy space where I decompress, diamond paint, and talk through the emotional weight of everyday life.This series is for those of us who are just trying to feel like ourselves again one tiny sparkle at a time. No filters, no scripts, no pressure. Just real talk while I work on something that feeds my soul.In this first episode, I'm catching you up on life lately, how I've been feeling, and where my head's been. It's not polished. It's not planned. It's just me decompressing, rambling, and trying to process the chaos with a side of bling!

Listen in as Joseph Kim, MD, MPH, MBA, interviews Natalie, Orbach, PA-C, to learn about how she implemented patient-centered and individualized treatment plans to improve obesity care at her practice, includingDiscussing weight and how nutrition, physical activity, mental health, and pharmacotherapy strategies can helpMeeting patients where they are at and offering slow, incremental changes that support long-term outcomesReferring patients to community resources and other professionals as needSharing lessons learned for those interested in implementing similar strategies in their practice PresenterJoseph Kim, MD, MPH, MBAPresidentQ Synthesis, LLCNewtown, PennsylvaniaNatalie Orbach, PA-CPhysician AssistantFeirtag & Ramos, PALutherville, Maryland Link to full program: https://bit.ly/45P0v8z

More and more people with type 1 are using GLP-1 receptor agonists. You know these medications, with brand names like Ozempic, Mounjaro, Wegovy and Zepbound, but none of them are specifically approved to treat T1D. Some of the first studies are underway to study the safety and effectiveness of GLP-1s, but that hasn't stopped thousands of using them off-label or to treat obesity. We're talking to an endocrinologist and a clinical pharmacist about why they prescribe these meds to some of their type 1 patients, who they won't prescribe them for, and – I know you're already asking – how they get insurance coverage.   My guests are endocrinologist Dr. Adam Spitz and Clinical Pharmacist Georgina Farrow GLP news story Stacey references here Dr Spitz's medical thriller here This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at an upcoming Moms' Night Out event! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.

You ever lie in bed at night, thinking about all the things you're going to do tomorrow, like wake up early, eat better, clean the house, work out, be more present, but then tomorrow comes… and you're right back in survival mode? Girl, I get it! Please hear this: you're not lazy - you're at maximum capacity. In this episode, I'm getting real about the exhaustion of good intentions that never get met, the emotional weight of feeling stuck, and the shame that sneaks in when you know you're capable of more but can't seem to show up. If you're just getting by and tired of feeling like you're failing… this one's for you.

Did you know a daily weight loss pill might soon replace weekly injections for managing obesity? In this episode, I explore the exciting new development of a once-daily oral weight loss medication, oral semaglutide 50mg highlighting results from the OASIS 1 trial. With this, I explain how this pill could be a game-changer for people who are hesitant about injections like Wegovy or Zepbound. I break down how semaglutide works as a GLP-1 receptor agonist, the phases of drug development, and the impressive trial results showing an average 15% body weight loss in participants without diabetes. I also talk about common side effects, the FDA approval timeline, and what this could mean for patients looking for more accessible, convenient weight loss options. Curious about the future of weight loss treatments? Tune in to learn about a groundbreaking pill that could change everything.   Episode Highlight: Introduction of oral semaglutide 50mg as a potential weight loss pill  Explanation of how semaglutide works as a GLP-1 receptor agonist. Overview of the OASIS 1 phase 3 trial Breakdown of clinical trial phases and FDA approval process. Discussion of side effects Adherence rates and significant weight loss among participants. Insight into future FDA approval timelines and potential market release Importance of combining medication with lifestyle changes Considerations about insurance coverage and patient access   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH. Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014. In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss, where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

In this solo episode, Dr. Marianne explores how the growing popularity of GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro is reshaping the body diversity movement. As weight loss drugs become more widely used and celebrated, messages of fat liberation and weight-inclusive care are being challenged in new and complex ways. Dr. Marianne discusses the cultural effects of GLP-1s, the pressure many people feel to conform to changing body ideals, and what this means for fat humans, eating disorder recovery, and those committed to body autonomy. This episode offers a compassionate and honest look at the grief, confusion, and questions arising in this new era. If you're navigating the intersection of weight stigma, eating disorders, and the rise of GLP-1 medications, this conversation will help you feel grounded, supported, and less alone.

In a groundbreaking development for the digital health world, Eli Lilly, one of the world's largest pharmaceutical companies, has filed lawsuits against a growing number of telehealth companies over the sale of compounded drugs Mounjaro and Zepbound, two popular GLP-1 medications. Nawa Lodin, Associate, Wilson Sonsini Goodrich & Rosati, and Lauren Petrin, Associate, Wiley Rein, discuss the background of compounding and when it is allowed under FDA regulations; the legal and regulatory issues at play in Eli Lilly's lawsuits, including issues related to the corporate practice of medicine and FDA regulations; and key compliance considerations. Watch this episode: https://www.youtube.com/watch?v=XstaVQGtY24AHLA's Health Law Daily Podcast Is Here! AHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Premium members. Get all your health law news from the major media outlets on this new podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast.

In this powerful and unapologetic episode, I sit down with Dr. Tyna Moore — physician, author, and outspoken advocate for evidence-based metabolic health — for a deeply candid conversation about peptides, GLP-1s (like Ozempic, Mounjaro, Wegovy, and Zepbound), and why the current medical system is failing women. We dive into:

The name of the biopharma game this season is vaccines—and RFK Jr. wasted no time returning from Memorial Day Weekend before making news on this front, removing the COVID-19 vaccine from the list of recommended immunizations for healthy kids and pregnant women on Tuesday. This follows a rash of recent moves, including a new risk-based strategy for the approval of new COVID vaccines focused on adults over 65 and high-risk individuals six months to 64 years of age and a request that Moderna and partners Pfizer and BioNTech update the myocarditis risk on their vaccines' labels.This increased vaccine scrutiny by the FDA and Department of Health and Human Services is having a significant impact on biopharma companies, several of whom have received stop-work orders on next-gen COVID vaccines. Meanwhile, Moderna last week pulled the biological license application for its combination COVID-19/flu vaccine, anticipating a request for additional data on flu shot efficacy from the FDA, as mRNA technology continues to be scrutinized after playing the hero during the pandemic. Also last week, the White House released its Make America Healthy Again (MAHA) report, which took aim at vaccines, along with pharma lobbying and GLP-1s.Also on the policy front, a California judge issued an order Thursday that indefinitely stops HHS' goal of reducing its divisions from 28 to 15 and firing upwards of 10,000 employees, among other reorganization and mass layoff plans. And speaking of government plays that could receive judicial pushback, we received a couple of new updates on the Most Favored Nation (MFN) front: first, President Donald Trump appointed his CMS chief Mehmet Oz as the leader of drug pricing negotiations, calling him “one tough hombre,” and second, HHS provided new guidance for streamlining the process for states to import drugs from Canada.In the obesity realm, Eli Lilly is calling out the Centers for Medicare and Medicaid Services. In an open letter last week, Lilly voiced its displeasure with the agency for a final ruling that left its Zepbound and Novo Nordisk's Wegovy out of Medicare Advantage and Part D coverage in 2026.And in the R&D realm, we returned from the long weekend to sad news from Rocket Pharmaceuticals, as the company reported that its pivotal Danon disease trial is on hold after the death of a young patient. The death—extremely sad on a human level—is also a setback for the gene therapy space, which had been buoyed earlier this month by the success of a personalized CRISPR treatment received by baby KJ.Finally, BioSpace looks ahead to ASCO#25 where Dan Samorodnitsky will be on the ground in Chicago.

Dr. Fiona Lovely is a longevity, health and wellness expert with specialties in menopause medicine, functional neurology, and functional medicine. She is speaking to the topics of women's health around perimenopause and menopause. In this week's episode, Dr. Fiona Lovely sits down with Angelo Keely, nutrition and protein optimization enthusiast.  Together, they dive into the powerful, science-backed role of protein and amino acids in supporting women's health—especially in midlife and beyond. Angelo unpacks why protein needs actually increase with age, particularly for women going through menopause. From fighting muscle loss (sarcopenia) to supporting bone health, metabolism, and mood, getting enough high-quality protein is essential—but often overlooked. You'll learn smart strategies to meet your protein goals without overeating, the key differences between protein powders and essential amino acids (EAAs), and how targeted supplements like creatine and EAAs can dramatically boost muscle and cognitive health—even without intense workouts. They also address the risks of rapid weight loss with GLP-1 medications (like Ozempic or Zepbound), and how pairing these with resistance training and amino acid support can help preserve lean mass and vitality. Topics We Cover in This Episode: Why women over 40 need more protein, not less How sarcopenia sneaks in—and how to stop it High-protein food tips: egg whites, Greek yogurt, lean meats & more EAAs vs. protein powder: what your body really absorbs NASA studies, amino acids & maintaining muscle without exercise Creatine for women: not just for gym bros GLP-1s & supporting strong muscles when taking it Simple, sustainable tips for strong, energized aging You can find more about Angelo and KION and about the Aminos product we speak about in this epsiode by visiting getkion.com/lovely (and there is a 20% off code - LOVELY) “Breathe. Be patient. Trust the process.” – Angelo Keely

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)Ever lost a lot of weight like 40, 50 pounds or more and noticed some unexpected changes in your body?In today's episode, we're talking about the surprising (and sometimes downright weird) side effects that don't get mentioned much when it comes to major weight loss—whether it's from lifestyle changes or medications like Zepbound or Wegovy.For example, some people develop Eustachian tube dysfunction, which can make your ears feel blocked or pop unexpectedly. Sitting might even feel uncomfortable now that the fat cushioning your tailbone is gone.Then there's “slimmer's paralysis”—a temporary nerve irritation that can pop up when the fat around certain nerves disappears. You might also spot new lumps or bumps, or find yourself feeling colder than usual since fat helps keep you warm.Other changes can include lower blood pressure and shifts in your menstrual cycle as your body adjusts.Want to hear more about these lesser-known effects and how to deal with them? Tune in to the full episode!Connect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

✨ My GLP-1 Girlie group program is opening again at the end of February for enrollment for a 3/2/25 start date.

Episode 2647: Vinnie Tortorich and Chris Shaffer discuss traveling, going down a bad road with GLP-1s and muscle loss, and more. https:vinnietortorich.com/2025/05/going-down-a-bad-road-episode-2647 PLEASE SUPPORT OUR SPONSORS YOU CAN WATCH ALL THE PODCAST EPISODES ON YOUTUBE -  Going Down A Bad Road Vinnie is traveling soon and is looking forward to going back home for crawfish season. (2:30) A good road trip is a nice “mental massage.” (5:15) He shares what he packs for the road trip. All of Vinnie's businesses will be consolidated into one website soon. (16:00) Pure Vitamin Club, Pure Coffee Club, and NSNG Foods will be available on one website. Chris brings up Good Morning America and GLP-1s. (18:00) Zepbound is being touted as the most effective, but, of course, it will come at a cost. The drastic loss of muscle is a concern; after all, your heart is a muscle! Ten percent (the low-end percentage) of muscle loss in the 60 to 72 week time span is the same as 20 yearsof sarcopenia. (25:00) They give an example of a VIP member who has been slow to lose weight; however, they have figured out this person is undereating! Your metabolism can slow down if you aren't getting enough calories. It can be as simple as adding another egg or two to make sure you are getting enough. This is the challenge with intermittent fasting and OMAD (one meal a day) approaches to eating. If you allow yourself to eat a treat, just get right back on the NSNG® plan. If you aren't sure how to get started with NSNG®, get Vinnie's e-book.  Chris shares some of his weight loss journey.  (42:00) He discovered his wheat and gluten sensitivity after stopping eating certain foods like pizza and pasta. Now he is so well-tuned with his health, he can tell if even a small amount of wheat is in his food. Avoid processed foods; they are addictive and damaging to your health. More News If you are interested in the NSNG® VIP group is currently closed for registration, but you can get on the wait list - Don't forget to check out Serena Scott Thomas on Days of Our Lives on the Peacock channel.  “Dirty Keto” is available on Amazon! You can purchase or rent it . Make sure you watch, rate, and review it! Eat Happy Italian, Anna's next cookbook, is available!  You can go to  You can order it from .  Anna's recipes are in her cookbooks, website, and Substack–they will spice up your day!  Don't forget you can invest in Anna's Eat Happy Kitchen through StartEngine.  Details are at Eat Happy Kitchen.  There's a new NSNG® Foods promo code you can use! The promo code ONLY works on the NSNG® Foods website, NOT on Amazon. https://nsngfoods.com/   PURCHASE  DIRTY KETO (2024) The documentary launched in August 2024! Order it TODAY! This is Vinnie's fourth documentary in just over five years. Visit my new Documentaries HQ to find my films everywhere:  Then, please share my fact-based, health-focused documentary series with your friends and family. Additionally, the more views, the better it ranks, so please watch it again with a new friend! REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! PURCHASE BEYOND IMPOSSIBLE (2022) Visit my new Documentaries HQ to find my films everywhere:  REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! FAT: A DOCUMENTARY 2 (2021) Visit my new Documentaries HQ to find my films everywhere:  FAT: A DOCUMENTARY (2019) Visit my new Documentaries HQ to find my films everywhere: 

In this episode of the Irresistible You podcast, we're talking about the importance of finding your soul snack—something that feeds your soul so you're not constantly turning to food for comfort. Since Chuy passed away, my nights have felt painfully quiet. He was my constant companion during the late-night hours when the house finally settled. That kind of loss leaves a void, but here's the thing… I didn't slip back into emotional eating, and that's because I already had the Irresistible You framework to guide me.One of the most powerful tools in that framework? Feed Your Soul.Lately, diamond painting has been helping me fill that space with peace instead of food. Let's talk about why you need a soul snack and how to find one that works for you.If you've ever reached for food when what you really needed was something deeper, this episode is for you.

Listen as Gaining Health host, Karli Burridge, reflects on the OMA Annual Conference with Sam and Joe!Petition to keep Zepbound on formulary:  https://www.change.org/p/stop-cvs-caremark-s-zepbound-ban-restore-coverage-of-the-superior-obesity-medicationSandra Christensen is board-certified as a family nurse practitioner and holds the Certificate of Advanced Education in Obesity Medicine from the Obesity Medicine Association. She is the founder and Chief Clinical Officer of Integrative Medical Weight Management in Seattle, Washington, and has specialized in obesity management since 2005. She is a Master Fellow of the Obesity Medicine Association and a Fellow of the American Association of Nurse Practitioners. She serves on the Board of Trustees for the Obesity Medicine Association and is the President of the Washington Obesity Society.  She authored the book, “A Clinician's Guide to Discussing Obesity with Patients” published by Springer, and was named the 2022 Obesity Medicine Association Clinician of the Year.The Washington Obesity SocietyIntegrative Medical Weight Managementhttps://www.linkedin.com/in/sandra-christensen/Joseph Zucchi (pronounced Zoo-key) is a board-certified Physician Assistant and Personal Trainer who serves as the Clinical Supervisor of Transition Medical Weight Loss in Salem, New Hampshire. With over a decade of experience in obesity medicine, Joe leads a multidisciplinary team dedicated to helping patients achieve sustainable weight loss and improved health. He has worked with over 2,000 patients to collectively lose more than 40,000 pounds. Joe integrates fitness, nutrition, and medical interventions to provide comprehensive, patient-centered care.  His work has been recognized through multiple accolades, including leading Transition Medical Weight Loss to win awards for best weight loss center in NH. He has written articles and has shared his expertise on obesity care and weight-loss treatments in outlets like the Wall Street Journal, MedPage Today, Healthline, and Doximity. Joe also is a speaker for Eli Lilly and educates other providers about Zepbound and obesity medicine. https://www.linkedin.com/in/josephzucchi/https://x.com/JPZfitnesshttps://transitionsalem.com/Support the showThe Gaining Health Podcast will release a new episode monthly, every second or third Wednesday of the month. Episodes including interviews with obesity experts as well as scientific updates and new guidelines for the management of obesity.If you're a clinician or organization looking to start or optimize an obesity management program, and you want additional support and resources, check out the Gaining Health website! We offer a Roadmap to starting an obesity program or practice, pre-recorded Master Classes, digital resources including patient education materials and office forms, and much more! Check out our resources on our Gaining Health Shop! If you are loving this podcast, please consider supporting us on Patreon

Join the Substack here: onthepen.substack.com Get all my links here: https://linktr.ee/manonthemounjaro

✨ My GLP-1 Girlie group program is opening again at the end of February for enrollment for a 3/2/25 start date.

Did you know that some weight loss medications can help people lose up to 20% of their body weight, comparable to bariatric surgery outcomes? In this episode, I dive into the latest research comparing two major weight loss medications, Wegovy (semaglutide) and Zepbound (tirzepatide), based on findings from the 72-week SURMOUNT-5 trial. I explain how Zepbound led to greater weight loss (about 20.2% vs. 13.7% with Wegovy), possibly due to its dual action on GIP and GLP-1 receptors. Both drugs were generally well tolerated, with similar side effects like nausea and constipation, though Wegovy had slightly more people stop due to GI issues. I also emphasize that while Zepbound may appear more effective, individual needs, such as cardiovascular health or sleep apnea, should guide treatment decisions. Lastly, I remind you that sustainable weight loss requires patience, realistic expectations, and a holistic approach that includes lifestyle changes, not just medication. Tune in to this episode to learn which weight loss medication might be right for you and why your journey to health is more than just the number on the scale.   Episode Highlights: Comparison of Wegovy (semaglutide) and Zepbound (tirzepatide) Average weight loss outcomes and waist circumference changes between both medications Mechanism of action: GLP-1 vs. dual GIP/GLP-1 receptor targeting Side effect profiles and tolerability of both medications FDA approval differences, including cardiovascular risk reduction and sleep apnea treatment Importance of personalized treatment plans and setting realistic weight loss expectations Ongoing research into oral formulations and long-term safety studies Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

There is an abundance of data on the impact of coffee drinking on health. Dr. Lisa shares the data on the way coffee impacts our risk for premature death, diabetes, depression, heart disease, stroke, Parkinson's disease, dementia, and other health conditions. She also dives in to the impact of coffee on weight loss, of course. And for those taking GLP1 agonists like Wegovy or Ozempic (or GLP/GIP meds like Zepbound or Mounjaro), she reviews the data on coffee and sarcopenia, which is muscle loss.This episode is filled with myth busting surprises about coffee and health. Of course there are downsides to coffee, so if you're pregnant, or you find that coffee causes palpitations, worsening anxiety, or insomnia for you, then it's probably time to rethink your drink or cut down on your coffee. Thanks for listening! If you'd like more support during your SMART weight loss & health focused journey, sign up for our FREE newsletter, or check out our program at: www.SmartWeightLossCoaching.com. We would love to help you reach your happy weight, and transform the way you talk to yourself about your body and the number on the scale. Negative thoughts about yourself don't have to take up so much brain space, and we'd be honored to help you reframe those thoughts. Also…We'd be grateful if you'd follow us and share our podcast with your friends & family. We're here to help you (and those you love) improve your health, live longer, healthier, and lose weight the SMART way! This episode was produced by The Podcast Teacher: www.ThePodcastTeacher.com.

President Donald Trump unveiled a sweeping drug pricing policy this week, seeking to lower drug prices in the U.S. by up to 80% through a reprisal of the Most Favored Nation rule he attempted to introduce in his first term. The rule would essentially link U.S. prices to those paid in other nations where medications are cheaper. Biopharma reaction was one of tentative relief, with BMO Capital Markets analysts suggesting the executive order had “more bark than bite.” Meanwhile, the Centers for Medicare and Medicaid Services announced that among the next 15 drugs to undergo IRA-prescripted price negotiations could be drugs payable through Medicare Part B, and not just Part D, where the first two rounds have applied.  Into all of this action steps Vinay Prasad, the outspoken oncologist and hematologist who was named last week as the next director of the FDA's Center for Biologics Evaluation and Research. While the S&P Biotech ETF fell by more than 5% upon the news, overall reaction was fairly measured, with cell and gene therapy executive Audrey Greenberg summing up Prasad's selection as “anything but a status quo appointment.”  Over in the weight loss and obesity space, Eli Lilly can't seem to lose. This weekend, Lilly announced full data from a head-to-head trial showing a “superior benefit-to-risk ratio” for its Zepbound over Novo Nordisk's Wegovy. And last week, the Indiana-based pharma won a court battle against compounders when a judge sided with the FDA, stating that tirzepatide—the active ingredient in both Zepbound and diabetes sister drug Mounjaro—was no longer in shortage. Add on a presidential shoutout during Trump's Monday press conference for its U.S. manufacturing investments, and it really was Lilly's week.  Flying less high are some 2,000 Bayer employees who lost their jobs in the first quarter of 2025 as part of the company's new operating model, which is intended to make Bayer “much more agile.” On a less direct flight is Galapagos, which reversed course on plans to spin out a portion of the company and find a new CEO. Instead, CEO Paul Stoffels will make a quicker exit and the Belgian biotech could sell off its cell therapy assets as it looks to build up a new pipeline in house, having abandoned the spinout idea altogether. Stay tuned.  Finally, in ClinicaSpace this week, we took a deep dive into the HIV treatment space, where companies like Gilead and Immunocore are targeting a cure, while the Trump administration slashes funding for HIV research.  

Joe's Petition + All My Links: https://linktr.ee/manonthemounjaro

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about President Trump’s new pick for surgeon general, Zepbound beating Wegovy for weight loss in the first head-to-head trial of blockbuster drugs, and measles cases still rising.

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about President Trump’s new pick for surgeon general, Zepbound beating Wegovy for weight loss in the first head-to-head trial of blockbuster drugs, and measles cases still rising.

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about President Trump’s new pick for surgeon general, Zepbound beating Wegovy for weight loss in the first head-to-head trial of blockbuster drugs, and measles cases still rising.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The White House has announced a new drug pricing policy that includes the revival of the most favored nations rule and extends to the private markets, leveraging the patent system, drug importation, and more. Meanwhile, Lilly's Zepbound has been found to have a superior benefit-risk ratio compared to Novo's Wegovy, BMS and Sanofi settle a Plavix lawsuit with Hawaii for $700 million, and biopharma companies are focusing on developing a cure for HIV as federal funding for related research is being cut. Sino Biological offers comprehensive solutions for autoimmune diseases, and Roche promises a $300 million investment in China production after a multibillion-dollar investment in the US. On the other hand, Lexeo and IGM have both announced significant layoffs. Novartis CEO has expressed concerns about Trump's pricing controls.Funding for HIV-related research and infrastructure is being cut by the Trump administration, leading biopharma companies like Gilead and Immunocore to focus on finding a cure for HIV. In the field of neurology, there is a need for more precise diagnostic tools to effectively treat neurodegenerative conditions. The new HHS vaccine requirement has been criticized by leading vaccine physician Paul Offit as potentially being anti-vaccine activism disguised as policy. Companies like Novartis, Bayer, and AstraZeneca are exploring new indications and innovations in radiopharmaceuticals, hoping to capitalize on a market that could reach $16 billion by 2033. The FDA has faced delays in reviewing certain drugs, while biotech stocks have fallen after the appointment of Vinay Prasad to succeed Marks at CBER. Vertex has decided to abandon AAV in the gene therapy space.Upcoming events include a webinar on surviving and thriving in the biotech downturn. Job opportunities in the biopharma industry include positions at Takeda, Daiichi Sankyo, and AbbVie. Heather McKenzie, senior editor at BioSpace, is open to suggestions for future coverage topics in neuroscience, oncology, cell & gene therapy, metabolic, or other areas.

Tirzepatide is more effective for weight loss than semaglutide.Cost-effectiveness is crucial in prescribing weight loss medications.Patients with severe obesity should receive more expensive medications for better outcomes.Both medications show significant benefits for obesity-related conditions.Long-term studies indicate sustained weight loss with both drugs.Gender differences affect weight loss outcomes with these medications.Safety profiles show tirzepatide may be better tolerated than semaglutide.The need for affordable drug pricing is emphasized.Clinical benefits extend beyond weight loss to include metabolic health.Future studies are needed to confirm cardiovascular benefits of tirzepatide.Click here to see the studyClick here to join Dr. Spencer's new online clinic

✨ My GLP-1 Girlie group program is opening again at the end of February for enrollment for a 3/2/25 start date.

La familia Real de Catar regaló a Donald Trump un lujoso avión valorado en más de 400 millones de dólares.En otras noticias: Con una nueva orden ejecutiva el presidente Trump espera reducir entre el 30% y 80% el precio de los medicamentos recetados. ¿Qué tan viable es?El Departamento de Seguridad Nacional inició una investigación para verificar si el condado de Los Ángeles proporcionó desde el 2021beneficios a personas indocumentados.Un juez federal autorizó que IRS comparta información fiscal confidencial con las autoridades migratorias para ayudar a localizar y deportar a inmigrantes indocumentados bajo investigación criminal.Hamás liberó al soldado estadounidense-israelí Edan Alexander.Comenzó el juicio contra Sean Diddy Combs en Nueva York en medio de escabrosas declaraciones. 

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Novo Nordisk predicts a brighter future for Wegovy with the end of the semaglutide shortage, but analysts remain skeptical as Eli Lilly's Zepbound gains ground in sales. The new HHS vaccine requirement has raised questions about its true intentions, with leading vaccine physician Paul Offit criticizing the lack of clarity. Meanwhile, pharmaceutical imports from Ireland are on the rise, biotech stocks fell after Vinay Prasad was named to succeed Marks at CBER, and Lotte Biologics' ADC facility in Syracuse offers end-to-end services for antibody manufacturing. CRISPR's Casgevy is gaining traction with more gene therapy proof of concept expected in 2025, impacting M&A and IPOs in the biotech industry. Summit Pharmaceuticals is nearing the first global phase III data for Keytruda, set to lose exclusivity in 2028 and potentially face competition from biosimilars. A report suggests that low-price drug nations are benefiting from US innovation, undervaluing innovative medicines by 90%. VC financing in biopharma declined by 20% in Q1, but megarounds kept the median deal size high. M&A and IPOs faced challenges due to policy issues, leading to an increase in licensing deals. Novo vows to improve market access for Wegovy, while Trump orders FDA to ease US plant expansion and increase inspections of foreign facilities. BMS pledges a $40 billion investment in the US, Novartis makes M&A moves, and Lilly remains unfazed by CVS's decision to side with Novo in the obesity market battle. Some drugmakers are stockpiling products in the US amid Trump's trade war. NGM terminates half of its staff as its lead asset moves through a registrational study. Job opportunities in clinical quality assurance audit, RBQM central statistical monitoring, and field medical capabilities are available.

Driveway Beers PodcastBig Weight Loss News!!We're back talking about weight loss. Mike and Alex talk about where their weight is with the first part of Spring behind us. Was there weight loss or weight gain and what's the plan moving forward? The fellas have some big news to share in this one! Please subscribe and rate this podcast on your podcast platforms like Apple and Spotify as it helps us a ton. Also like, comment, subscribe and share the video on Youtube. It really helps us get the show out to more people. We hope you enjoyed your time with us and we look forward to seeing you next time. Please visit us at https://drivewaybeerspodcast.com/donate/ to join The Driveway Club and buy us a bourbon! Buy us a bottle and we'll review it on a show!Leave us a comment and join the conversation on our discord at https://discord.gg/rN25SbjUSZ.Please visit our sponsors:Adam Chubbuck of Team Alpha Charlie Real Estate, 8221 Ritchie Hwy, Pasadena, MD 21122, www.tacmd.com, (443) 457-9524. If you want a real estate agent that will treat your money like it's his own and provide you the best service as a buyer or seller, contact Adam at Team Alpha Charlie.If you want to sponsor the show, contact us at contact@drivewaybeerspodcast.comCheck out all our links here https://linktr.ee/drivewaybeerspodcast.comIf you're looking for sports betting picks, go to conncretelocks.com or send a message to Jeremy Conn at Jconn22@gmail.comFacebook Page https://www.facebook.com/drivewaybeerspodcast/#podcast #whiskey #bourbon

Join Dr. Emily Cooper, Andrea Taylor, and Mark Wright on Fat Science for a special mailbag episode answering listener questions about metabolic health. Dr. Cooper explains the difference between mindful and mechanical (timed) eating, especially for those using medications like Zepbound. The team also addresses emotional challenges tied to frequent eating, societal fat shaming, and the complexities of medication side effects for those on GLP-1 agonists and antipsychotics. Real experiences and practical advice help shed light on fueling your body, breaking free from diet culture guilt, and navigating complex emotions on the journey to better health.Key Takeaways:GLP-1 medications like Zepbound affect appetite and metabolism but can also suppress hunger cues; mechanical eating—timing meals and including all food groups—prevents nutritional deficits and supports long-term metabolic health.Eating too few calories, even when appetite is low, can be detrimental; mechanical eating helps maintain muscle mass and prevent stalled metabolism.Emotional barriers, guilt, and anxiety around food are common due to fat shaming and past dieting experiences. Meal planning and support from dietitians can help ease this transition.GLP-1s may alter medication absorption or trigger anxiety episodes due to blood sugar fluctuations; monitoring and professional advice are recommended when combining with psych meds.Personal Stories & Practical Advice:Andrea shares strategies for getting enough nutrition when appetite is low, her experiences with fat shaming, and her approach to enjoying food without guilt.Mark and Dr. Cooper discuss breaking free from restrictive food mindsets and building a positive, fuel-focused relationship with eating.Key Takeaways:Resources:Connect with Dr. Emily Cooper on LinkedIn.Connect with Mark Wright on LinkedIn.Connect with Andrea Taylor on Instagram.Fat Science is a podcast on a mission to explain where our fat really comes from and why it won't go and stay away. We are committed to creating a world where people are empowered with accurate information about metabolism and recognize that fat isn't a failure. This podcast is for informational purposes only and is not intended to replace professional medical advice.If you have a question for Dr. Cooper, a show idea, feedback, or just want to connect, email us at info@diabesityinstitute.org or dr.c@fatsciencepodcast.com.Science is supported by the non-profit Diabesity Institute which is on a mission to increase access to effective, science-based medical care for those suffering from or at risk for diabesity. https://diabesityresearchfoundation.org/

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Lilly's revenue jumped by 45% in the latest quarter, driven by the success of their drugs Zepbound and Mounjaro. Moderna missed revenue expectations for the first quarter but plans to cut $1.5 billion in costs. Biogen executives are dealing with tariffs, but believe the impact will be minimal. The Department of Health and Human Services announced a new policy requiring placebo-controlled trials for all new vaccines, which has been met with criticism from experts. Trilink Biotechnologies has introduced custom sets of mRNA for screening studies. In other news, CVS has chosen Novo's side in the obesity market battle, RFK Jr. is sparking controversy in vaccine discussions, and J&J has entered the myasthenia gravis market. Additionally, AstraZeneca faced a setback with their drug Truqap in a phase III prostate cancer study.

CVS announces major partnership with Novo Nordisk as Lilly announces Q! 2025 earnings. Dave covers it all in today's breakdown. Join the Substack: https://substack.com/@onthepen WAYS TO SUPPORT MY WORK ⬇️

Join the Substack: https://substack.com/@onthepen WAYS TO SUPPORT MY WORK ⬇️

Send a Text Message. Please include your name and email so we can answer you! Please note, this does not subscribe you to our email list, it's just to answer if you have a questions for us. It's an exciting time to be practicing in obesity medicine, with groundbreaking tools like Zepbound and Wegovy helping people achieve their weight loss goals in ways that were once unimaginable. Plus, with new medications like retatrutide (the triple agonists) on the horizon, the future of weight management is looking even brighter.But with so many options available, it can be overwhelming to figure out which medication is right for you. How do Zepbound and Wegovy compare? Can you switch between the two? Is one more effective than the other? In this episode, I'll dive into the key differences between Zepbound (Mounjaro) and Wegovy (Ozempic), comparing doses, effectiveness, and answering all your burning questions about how these medications stack up against each other. ReferencesThe Top 5 Mistakes People Make When Starting GLP-1 Season 1 of the Premium Podcast: The Obesity Guide: Behind the CurtainAudio Stamps00:30 - Dr. Rentea sets the stage for a back-to-basics breakdown of Wegovy vs. Zepbound, which touches on key topics like switching, dosing, and access.01:58 - A comparison of Wegovy (GLP-1) and Zepbound (dual GLP-1 and GIP), discussing their average weight loss effects and varying response rates.05:19 - Dr. Rentea discusses the reasons someone might consider switching medications.06:45 - Switching medications shouldn't involve restarting titration, and working with a knowledgeable physician to manage transitions effectively is key.11:45 - Medication can be a helpful tool, but long-term success depends on working with a skilled physician and staying focused on sustainable progress.Quotes“Within the first few months, it's going to become very clear. Do you need an additional tool? Do we need to tweak things? Do we need to change things?”“These are medications, but they're not everything. You still have to do the heavy lifting on the lifestyle aspect behind the scenes. But you have the ability to switch from one to the other.”“You really should be working with someone who is very familiar with these medications, with switching medications, with adding other things to it, with changing things. There is always something else that can be done.”“We do sometimes see higher results with ZepBound, but there's going to be other medication that comes out that's potentially higher than that. At the end of the day, it's what helps me to keep doing all the other things.”All of the information on this podcast is for general informational purposes only. Please talk to your physician and medical team about what is right for you. No medical advice is being on this podcast. If you live in Indiana or Illinois and want to work with doctor Matthea Rentea, you can find out more on www.RenteaClinic.com Premium Season 1 of The Obesity Guide: Behind the Curtain -Dive into real clinical scenarios, from my personal medication journey to tackling weight loss plateaus, understanding insulin resistance, and overcoming challenges with GLP-1s. Plus, get a 40+ page guide packed with protein charts, weight loss formulas, and more. April 30/30 registration.

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.comWhy does starting a GLP-1 medication like Wegovy or Zepbound sometimes feel like your body—and your emotions—are on a whole new ride?If you've just started one of these meds, you might already be noticing some changes: that queasy feeling that sticks around a little too long, the bloating that makes jeans feel like a bad idea, or maybe even some unexpected mood shifts that leave you feeling off. Sound familiar?You're not imagining it. Nausea, reflux, constipation, diarrhea, and yes—even mood changes—are all common side effects people experience when adjusting to GLP-1 medications. And while it can feel a little overwhelming (and honestly frustrating), these symptoms are usually temporary—and more manageable than they seem.In this episode, we're talking about all the stuff no one really prepares you for: why these side effects happen, how your gut and brain are connected during this adjustment phase, and the small, practical changes that can actually make a difference. Whether you're in your first week or slowly increasing your dose, this info can help you feel more grounded—and a lot less stressed.Tap in for simple, science-backed advice to help you feel better, physically and emotionally.Connect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

✨ My GLP-1 Girlie group program is opening again at the end of February for enrollment for a 3/2/25 start date.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Eli Lilly will start a lcinical trial for tirzepatide for people with type 1 diabetes, more details on Dexcom's 15 day G7 sensor, Ozepmic pill form tested, type 5 diabetes identified and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Our top story this week.. Eli Lilly takes the first steps toward getting tirzepatide approved for people with type 1 diabetes. Tirzepatide is sold under the brand names Mounjaro for type 2 and Zepbound for obesity. The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or are overweight. Participation in the study will last about 49 weeks. Official Title A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Tirzepatide Once Weekly Compared to Placebo in Adult Participants With Type 1 Diabetes and Obesity or Overweight This is a big deal because, even though many people with type 1 are able to get a prescription for tirzepatide, it's not approved for T1D and so insurers won't usually cover it.   https://clinicaltrials.gov/study/NCT06914895 XX The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there's little information on the drugs' safety and effectiveness for the condition. The family of medications called GLP-1 receptor agonists includes drugs like Wegovy, Zepbound, Ozempic, Mounjaro and Victoza. But the clinical trials of these medications specifically excluded people with type 1 diabetes, who are dependent on the hormone insulin to survive because they can't make enough of their own. Drugmakers feared that using the GLP-1 medications with insulin might raise the chance of dangerously low blood sugar events, or hypoglycemia, and were unwilling to take the risk of studying them in people with type 1.   For the study, which was published last month in the journal Diabetes, Obesity, and Metabolism, researchers at Johns Hopkins University reviewed the medical records of more than 200,000 people with type 1 diabetes from 2008 to 2023. They grouped the data in three-year periods, starting with October 2008 to September 2011 and ending with October 2020 to September 2023. GLP-1 medication use spiked, as well. Among adults with the highest category of obesity, about 4% used GLP-1 medications in 2008, and 33% did by 2023 – an 800% increase. But these are anecdotal reports and may not reflect instances in which people have side effects or complications like low blood sugar, which can be life-threatening. But Shin says what's really needed is information from randomized, double-blinded studies, in which participants are followed forward in time and given either a drug or a placebo. https://www.cnn.com/2025/04/09/health/glp-1-type-1-diabetes-study/index.html   XX Later this month the FDA will conduct a final meeting regarding a new, investigational compound (sotagliflozin) soda-GLIFF-a-zin that has been shown to Improve QoL and Reduce Long-term Complications for people with type 1 diabetes (T1D). The patient advocacy group Taking Control of Your Diabetes (TCOYD.org) is working to inform the T1D community about sotagliflozin - and to encourage people to sign a Change.org petition directed towards FDA.  Last fall, the FDA declined to approve sotagliflozin due to concerns about a potential increased risk of diabetic ketoacidosis (DKA), despite this being a condition that people with T1D on insulin face and manage daily. While TCOYD respects FDA's caution, the group stands by T1D patients and their physicians who, as a team, balance risks and benefits every day. https://tcoyd.org/petition/ XX Dexcom receives FDA approval for it's G7 with 15 day wear. We have an interview with Chief Operating Officer Jake Leach coming up on Tuesday – we talk about the planned roll out of this sensor, what else has changed, and the fine print in the press release – it says    “A study was conducted to assess the sensor life where 73.9% of sensors lasted the full 15 days. When using the product per package labeling, approximately 26% of sensors may not last for the full 15 days.   https://investors.dexcom.com/news/news-details/2025/Dexcom-G7-15-Day-Receives-FDA-Clearance-the-Longest-Lasting-Wearable-and-Most-Accurate-CGM-System/default.aspx?utm_source=www.diabetech.info&utm_medium=referral&utm_campaign=dexcom-g7-15-day-sensor-gets-fda-cleared-but-will-it-actually-last-that-long   XX Glucotrack is joining something called  FORGETDIABETES bionic pancreas initiative, - this is an European Union project that aims to develop a long-term automated insulin delivery system for type 1 diabetes patients. Glucotrack's Continuous Blood Glucose Monitor (CBGM) will be integrated into the system to provide real-time glucose readings. The initiative's goal is to create a bionic invisible pancreas that eliminates the need for therapeutic actions and reduces psychological burden.   The architecture of BIP encompasses a ground-breaking, lifelong lasting implanted ip glucose nanosensor; a radically novel ip hormone delivery pump, with unique non-invasive hormone refill with a magnetic docking pill and non-invasive wireless battery recharge; an intelligent closed-loop hormone dosing algorithm, optimized for ip sensing and delivery, individualized, adaptive and equipped with advanced self-diagnostic algorithms.     Pump refilling through a weekly oral recyclable drug pill will free T1D subjects from the burden of pain and awkward daily measurement and treatment actions. Wireless power transfer and data transmission to cloud-based data management system round-up to a revolutionary treatment device for this incurable chronic disease. key feature of BIP is to be fully-implantable and life-long lasting thanks to novel biocompatible and immune-optimized coatings guaranteeing long-term safety and stability https://www.stocktitan.net/news/GCTK/glucotrack-to-participate-in-forgetdiabetes-a-prominent-european-cjjldjb0dq7h.html XX A newly recognised form of diabetes, called Type 5, was announced this week at the World Congress of Diabetes 2025. A global task force will investigate this less-understood condition, which differs from Type 1 and Type 2 diabetes. Type 5 diabetes affects people who are underweight, lack a family history of diabetes and do not show the typical symptoms of Type 1 or Type 2 diabetes. The condition was first observed in the 1960s and referred to as J-type diabetes, after being detected in Jamaica. It was classified by the World Health Organisation in 1985, but removed in 1998 due to lack of physiological evidence. At the time, experts believed it to be a misdiagnosed case of Type 1 or 2 diabetes. New research has since confirmed that Type 5 is different. https://economictimes.indiatimes.com/news/new-updates/a-new-type-of-diabetes-has-been-found-by-scientists-and-it-doesnt-show-the-typical-symptoms-of-type-1-or-type-2/articleshow/120276658.cms?from=mdr   XX Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. A new clinical trial, co-led by endocrinologist and diabetes specialist John Buse, MD, PhD, and interventional cardiologist Matthew Cavender, MD, MPH, at the UNC School of Medicine, has demonstrated that the oral form of semaglutide significantly lowers the risk of cardiovascular events in individuals with type 2 diabetes, atherosclerotic cardiovascular disease, and/or chronic kidney disease. Results from the rather large, international trial were published in the New England Journal of Medicine and presented at the American College of Cardiology's Annual Scientific Session & Expo in Chicago, Illinois.     The effect of oral semaglutide on cardiovascular outcomes was consistent with other clinical trials involving injectable semaglutide, but more trials are needed to determine if one method may be more effective than the other at reducing major cardiovascular events. https://scitechdaily.com/new-pill-form-of-semaglutide-shows-major-benefits-for-people-with-diabetes/ XX April 14 (UPI) -- The U.S. Food and Drug Administration on Monday warned consumers and pharmacies that fake versions of Ozempic, a drug to treat Type 2 diabetes, have been found in the United States. Novo Nordisk, the Danish-headquartered manufacturer, informed the FDA on April 3 that counterfeit 1-milligram injections of semaglutide were being distributed outside its authorized supply chain. The FDA and Novo Nordisk are testing the fake products to identify whether they're safe. Patients are asked to obtain Ozempic with a valid prescription through state-licensed pharmacies and check the product for any signs of counterfeiting. People in possession of the fake product are urged to call Novo Nordisk customer care at 800-727-6500 Monday through Friday from 8:30 a.m. to 6 p.m. EDT and report it to the FDA's criminal activity division's website. Side effects can be reported to FDA's MedWatch Safety Information and Adverse Event Reporting Program (800-FDA-1088 or www.fda.gov/medwatch) as well as to Novo Nordisk, at 800-727-6500. https://www.upi.com/Health_News/2025/04/14/FDA-fake-Ozempic-drugs-Novo-Nordisk/6841744666854/ XX Can a digital lifestyle modification program reduce diabetes risk? A new study shows that the lifestyle intervention significantly reduced 10-year diabetes risk among prediabetics by nearly 46% and increased the diabetes remission rate, highlighting the importance of lifestyle changes. However, the study was not a randomized trial, and participation in the lifestyle intervention was voluntary, which may introduce selection bias. The study evaluated 133,764 adults, categorizing them as diabetic (7.5%), prediabetic (36.2%), and healthy (56.3%), based on fasting glucose and HbA1c levels. https://www.news-medical.net/news/20250414/Digital-lifestyle-program-cuts-diabetes-risk-by-4625-in-prediabetics-study-of-130k2b-adults-reveals.aspx XX Chrissy Teigan is speaking out about her son's type 1 diagnosis – teaming up with Sanofi to encourage people to screen early for Type 1 diabetes.   Teigen got a crash course in the risks of undiagnosed Type 1 diabetes when her 6-year-old son, Miles, was hospitalized with complications of the autoimmune disease last year. The family knew nothing about Type 1 diabetes when Miles was diagnosed during an unexpected medical emergency, Teigen said in a Tuesday announcement. “We were confused and scared when Miles was first diagnosed,” she said in a statement. “There is no doubt in my mind that knowing in advance would have made a positive impact for Miles, me, and our entire family. I want everyone to hear me when I say: stay proactive and talk to your doctor about getting yourself or your loved ones screened for type 1 diabetes today!”   Teigen shared her family's story in a two-minute video on ScreenForType1.com, a Sanofi website that discusses how to get screened for the condition. Miles' diagnosis made Teigen feel like she “went from a mom to a doctor overnight,” she said. That experience is why Teigen said she is “begging you: Do this one thing, and screen yourself and your family for Type 1 diabetes.” https://www.fiercepharma.com/marketing/sanofi-signs-chrissy-teigen-diabetes-screening-campaign XX Dr. Richard Bernstein – best known for his advocacy around low carb diets for people with diabetes – died this week at the age of 90. Born in 1934 in Brooklyn, New York, he was diagnosed with type 1 at age 12. In the 1970s he adapted a blood glucose monitor for home use and helped pioneer home glucose monitoring. He published multiple books on Diabetes including the #1 selling Diabetes book on Amazon.Com “Dr. Bernstein's Diabetes Solution: A Complete Guide to Achieving Normal Blood Sugars” and “Diabetes Type II: Living a Long, Healthy Life Through Blood Sugar Normalization”.  He practiced and saw patients right up until his death.

Subscriber-only episodeResources for the Community:___________________________________________________________________https://linktr.ee/theplussidezpodcast Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55______________________________________________________________________The Provider Spotlight is a bonus series of shorter episodes featuring doctors and specialists from past sessions—think of it as 'doctor shorts.' With over 25k scripts for Zepbound written weekly, many new subscribers haven't seen our earlier episodes, which helps them catch up quickly. Thanks for your support! Dr. Salas-Whalen joins The Plus Sidez to break down PCOS, insulin resistance, and metabolic disorders—and how they're all connected. ______________________________________________________________________⭐️Mounjaro Stanley⭐️griffintumblerco.Etsy.comUse code PODCAST10 for $ OFF______________________________________________________________________Join this channel to get access to perks:   / @theplussidez______________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovy Kim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

Medicare and Medicaid to deny coverage for weight loss drugs, as Weight Watchers files for bankruptcy; Overactive bladder may be a consequence of poor nutritional status; The paradox of how exercise helps mental fatigue; Breakthrough cases of measles may not just be about vaccine refusal; The power of urolithin A (Mitopure™️) to boost energy and slow aging.

Subscriber-only episodeResources for the Community:___________________________________________________________________https://linktr.ee/theplussidezpodcast Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55______________________________________________________________________This episode delves into the powerful journey of emotional healing and reclaiming a healthy relationship with food through GLP-1 treatment, specifically Zepbound. Featuring Noelle and Danielle, who have transformed their lives with Ro's obesity treatment program, Ro Body Program, we explore the complex interplay between mental health, body image, and body dysmorphia.We discuss how emotional symptoms, including body dysmorphia, can hinder weight loss progress and distort perceptions of achievement, especially for those dealing with eating disorders. The conversation also emphasizes the critical role of self-compassion in navigating setbacks and avoiding diet-culture spirals, alongside actionable strategies for healing and breaking free from the "never enough" mentality.At the heart of this discussion is the importance of self-love, not just as a tool for overcoming body image struggles, but as a cornerstone for long-term emotional well-being. This episode is about more than just weight loss—it's about restoring mental and emotional balance while living in an obese body, offering insights into how Zepbound and GLP-1 treatments can play a vital role in this transformative process.______________________________________________________________________⭐️Mounjaro Stanley⭐️griffintumblerco.Etsy.comUse code PODCAST10 for $ OFF______________________________________________________________________Join this channel to get access to perks:   / @theplussidez______________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovy  Kim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)Have you ever been told what to eat—but not how to actually make it?That gap between nutrition advice and real-life cooking is exactly what culinary medicine aims to fill. It's the bridge between knowing what supports your health and actually making it work in your kitchen and your lifestyle.In this episode, we're diving into the practical side of healthy eating—through the lens of culinary medicine. You'll hear from registered dietitian and public health expert Christina Badaracco, who leads culinary medicine training programs nationwide and recently co-authored a new cookbook called Mix It Up.We talk about:What culinary medicine really means (and why it matters)How teaching kitchens and group cooking programs help build skills and confidenceCommon barriers to cooking and how to overcome themCreative ways to bring culinary medicine into healthcare, community settings, and even your own homeChristina's journey writing Mix It Up and how it's designed to help beginners and hesitant cooks eat better without the overwhelmWe also dig into a big question: how can patients eat well—even when they're eating less, such as during treatment with medications like Wegovy or Zepbound? Christina shares the thinking behind flexible recipes, ingredient swaps, and why making every bite count doesn't have to mean complicated cooking.Whether you're a provider, patient, or just someone who wants to feel more at home in the kitchen, this conversation will leave you with tools, ideas, and a fresh perspective on food and health. Press play now to get started.Connect with Ms. Christina:Book: Mix It UpCo-Author's Website: Olivia ThomasWebsite: Christina BadaraccoLinkedin: Christina Badaracco, MPH, RDN, LDN Information about teaching kitchens: Growing the Value of Teaching Kitchens to Promote Healthy Cooking and Lifestyle BehaviorsTeaching Kitchen Collaborative members: https://teachingkitchens.org/member-list/Teaching kitchen training toolkit: https://teachingkitchens.org/toolkits/Characteristics of Current Teaching Kitchens: Findings from Recent Surveys of the Teaching Kitchen CollaborativeConnect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

Episode 2623: Vinnie Tortorich and Chris Shaffer discuss news items that address junk food in the SNAP program, weight loss drug risks, and more. https://vinnietortorich.com/2025/03/weight-loss-drug-risks-episode-2623 PLEASE SUPPORT OUR SPONSORS YOU CAN WATCH ALL THE PODCAST EPISODES ON YOUTUBE -  Weight Loss Drug Risks Several states are trying to ban junk foods from being purchased from the SNAP program. (10:00) Each state defines junk food differently, but many define it as soda and candy. (13:30) The focus is trying to get people to purchase whole foods. The American Heart Association is pushing back against this move. (21:00) The various reasons the AHA gives are discussed and not all of them make sense. Vinnie and Chris review the list of companies and how much they contribute to the AHA each year. (28:15) One excuse claims the number of products is “just too hard” to list. The UK is now banning ads for junk food. (35:45) They discuss the drug Jardiance and the health disclaimers at the end of the ad. (38:00) Next in the discussion is Zepbound, which was used for sleep apnea, but is also marketed as a weight loss drug. (47:30) Vinnie emphasizes that going low-carb will give you none of the side effects that the medications will have. More News If you are interested in the NSNG® VIP group, closed for registration, but you can get on the wait list - Don't forget to check out Serena Scott Thomas on Days Of Our Lives on the Peacock channel.  “Dirty Keto” is available on Amazon! You can purchase or rent it . Make sure you watch, rate, and review it! Eat Happy Italian, Anna's next cookbook is available!  You can go to  You can order it from .  Anna's recipes are in her cookbooks, website, and Substack–they will spice up your day!  Don't forget you can invest in Anna's Eat Happy Kitchen through StartEngine.  Details are at Eat Happy Kitchen.  There's a new NSNG® Foods promo code you can use! The promo code ONLY works on the NSNG® Foods website, NOT on Amazon. https://nsngfoods.com/   PURCHASE  DIRTY KETO (2024) The documentary launched in August 2024! Order it TODAY! This is Vinnie's fourth documentary in just over five years. Visit my new Documentaries HQ to find my films everywhere:  Then, please share my fact-based, health-focused documentary series with your friends and family. Additionally, the more views, the better it ranks, so please watch it again with a new friend! REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! PURCHASE BEYOND IMPOSSIBLE (2022) Visit my new Documentaries HQ to find my films everywhere:  REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! FAT: A DOCUMENTARY 2 (2021) Visit my new Documentaries HQ to find my films everywhere:  FAT: A DOCUMENTARY (2019) Visit my new Documentaries HQ to find my films everywhere: